Comparison of the design differences between the Ginkgo evaluation of memory study and the guidage study

Journal of Nutrition, Health and Aging

Volumn 12, Issue 1, 2008, Pages

  Williamson, Jeff D ^a   Vellas, B ^b   Furberg, C ^a   Nahin, R ^c   Dekosky, S T ^d  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b CHU PURPAN   (France)

^c National Institutes of Health   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GINKGO BILOBA EXTRACT;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL PARAMETERS;

GINKGO BILOBA;

EID: 38549096544     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02982591     Document Type: Conference Paper

References (47)

1. Guralnik JM, Leveille SG, Hirsch R, Ferrucci L, Fried LP. The impact of disability on older women. JAMWA 1997;52(3):113-120.
2. guero-Torres H, Fratiglioni L, Guo Z, Viitanen M, von SE, Winblad B. Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. Am J Public Health 1998 Oct;88(10):1452-1456.
3. Magsi H, Malloy T. Underrecognition of cognitive impairment in assisted living facilities. J Am Geriatr Soc 2005 Feb;53(2):295-298.
4. National Institute on Aging. Progress Report on Alzheimer's Disease. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service; 2000. Report No.: NIH Publication no. 00-4859.
5. Haines DD, Bak I, Ferdinandy P, et al. Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts. J Cardiovasc Pharmacol 2000 Jan;35(1):37-44.
6. Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 1997 Feb;29(2):733-742.
7. Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 1997 Feb;29(2):733-742.
8. Robak J, Gryglewski RJ. Flavonoids are scavengers of superoxide anions. Biochem Pharmacol 1988 Mar 1;37(5):837-841.
9. Tosaki A, Engelman DT, Pali T, Engelman RM, Droy-Lefaix MT. Ginkgo biloba extract (EGb 761) improves postischemic function in isolated preconditioned working rat hearts. Coron Artery Dis 1994 May;5(5):443-450.
10. Varga E, Bodi A, Ferdinandy P, Droy-Lefaix MT, Blasig IE, Tosaki A. The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts: a link between cardiac function and nitric oxide production. J Cardiovasc Pharmacol 1999 Nov;34(5):711-717.
11. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000 Feb;71(2):621S-629S.
12. Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996;36:83-106.
13. Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A 2002 Sep 17;99(19):12197-12202.
14. Rimbach G, Wolffram S, Watanabe C, Packer L, Gohil K. Effect of Ginkgo biloba (EGb 761) on differential gene expression. Pharmacopsychiatry 2003 Jun;36 Suppl 1:S95-S99.
15. Watanabe CM, Wolffram S, Ader P, et al. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci U S A 2001 Jun 5;98(12):6577-6580.
16. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 2000 Jun;12(6):1882-1890.
17. Brunetti L, Orlando G, Menghini L, Ferrante C, Chiavaroli A, Vacca M. Ginkgo biloba leaf extract reverses amyloid beta-peptide-induced isoprostane production in rat brain in vitro. Planta Med 2006 Nov;72(14):1296-1299.
18. Mahady GB. Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. J Cardiovasc Nurs 2002 Jul;16(4):21-32.
19. Marcocci L, Maguire JJ, Droy-Lefaix MT, Packer L. The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. Biochem Biophys Res Commun 1994 Jun 15;201(2):748-755.
20. Rioufol G, Pietri S, Culcasi M, et al. Ginkgo biloba extract EGb 761 attenuates myocardial stunning in the pig heart. Basic Res Cardiol 2003 Feb;98(1):59-68.
21. Huang SY, Jeng C, Kao SC, Yu JJ, Liu DZ. Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy. Clin Nutr 2004 Aug;23(4):615-621.
22. Koltringer P, Langsteger W, Klima G, Reisecker F, Eber O. [Hemorheologic effects of ginkgo biloba extract EGb 761. Dose-dependent effect of EGb 761 on microcirculation and viscoelasticity of blood]. Fortschr Med 1993 Apr 10;111(10):170-172.
23. Auguet M, DeFeudis FV, Clostre F. Effects of Ginkgo biloba on arterial smooth muscle responses to vasoactive stimuli. Gen Pharmacol 1982;13(2):169-171.
24. Chen X, Salwinski S, Lee TJ. Extracts of Ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway. Clin Exp Pharmacol Physiol 1997 Dec;24(12):958-959.
25. Haramaki N, Aggarwal S, Kawabata T, Droy-Lefaix MT, Packer L. Effects of natural antioxidant ginkgo biloba extract (EGB 761) on myocardial ischemia-reperfusion injury. Free Radic Biol Med 1994 Jun;16(6):789-794.
26. Sasaki Y, Noguchi T, Yamamoto E, et al. Effects of Ginkgo biloba extract (EGb 761) on cerebral thrombosis and blood pressure in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2002 Nov;29(11):963-967.
27. Fitzl G, Welt K, Schaffranietz L. Myocardium-protective effects of Ginkgo biloba extract (EGb 761) in old rats against acute isobaric hypoxia. An electron microscopic morphometric study. I. Protection of cardiomyocytes. Exp Toxicol Pathol 1996 Jan;48(1):33-39.
28. Liebgott T, Miollan M, Berchadsky Y, Drieu K, Culcasi M, Pietri S. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res Cardiol 2000 Oct;95(5):368-377.
29. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 2000 Mar;108(4):276-281.
30. Birks J, Grimley EV, Van DM. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002;(4):CD003120.
31. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003 May 28;289(20):2651-2662.
32. Williamson JD, Miller ME, Bryan RN, et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol 2007 Jun 18;99(12A):112i-122i.
33. Dekosky ST, Fitzpatrick A, Ives DG, et al. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 2006 Jun;27(3):238-253.
34. Fitzpatrick AL, Fried LP, Williamson J, et al. Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience. Contemp Clin Trials 2006 Dec;27(6):541-553.
35. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H. The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 2006 Nov 14;67(9 Suppl 3):S6-11.
36. Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996 Mar;29(2):47-56.
37. Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 1997 Nov;31(6):645-655.
38. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993 Nov;43(11):2412-2414.
39. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984 Nov;141(11):1356-1364.
40. Lopez OL, Becker JT, Somsak D, Dew MA, Dekosky ST. Awareness of cognitive deficits and anosognosia in probable Alzheimer's disease. Eur Neurol 1994;34(5):277-282.
41. Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ. A validation study of the Dementia Questionnaire. Arch Neurol 1994 Sep;51(9):901-906.
42. Jorm AF, Korten AE. Assessment of cognitive decline in the elderly by informant interview. Br J Psychiatry 1988 Feb;152:209-213.
43. Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. [Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level]. Acta Neurol Belg 1990;90(4):207-217.
44. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 Nov;12(3):189-198.
45. Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology 1988 Jun;38(6):900-903.
46. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9(3):179-186.
47. Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol 1955 Oct;19(5):393-394.